Literature DB >> 11418352

Maturation of IgG avidity to individual rubella virus structural proteins.

J Nedeljkovic1, T Jovanovic, C Oker-Blom.   

Abstract

BACKGROUND: the structural proteins of rubella virus, the capsid protein C and the envelope glycoproteins E1 and E2 were produced in lepidopteran insect cells using baculovirus expression vectors. The C-terminal ends of the corresponding proteins were fused to a polyhistidine tag for easy and gentle purification by metal ion affinity chromatography.
OBJECTIVES: to investigate the maturation of natural and vaccinal IgG avidity against individual authentic and recombinant rubella virus (RV) structural proteins. STUDY
DESIGN: the analysis was carried out using a modified immunoblotting technique where the purified baculovirus-expressed proteins were compared with authentic rubella virus proteins. Altogether, 47 well-characterised serum samples from both naturally infected patients and vaccines were studied.
RESULTS: after natural RV infection, IgG antibodies specific for the E1 protein were predominant not only in terms of levels, but also in terms of rate and magnitude of avidity maturation. The avidity development of the IgG antibodies was much slower in vaccines than in patients after a natural RV infection.
CONCLUSIONS: together, our results indicate that IgG avidity determination in conjunction with immunoblot analysis is useful in the diagnosis of a RV infection. The recombinant proteins showed similar reactivity patterns in the immunoblot analyses as compared with the authentic viral structural proteins, suggesting suitability for serodiagnostics.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418352     DOI: 10.1016/s1386-6532(01)00161-5

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  8 in total

1.  Evaluation of commercial rubella immunoglobulin G avidity assays.

Authors:  Samira Mubareka; Hannah Richards; Michael Gray; Graham A Tipples
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

2.  Immunogenicity of recombinant human bocavirus-1,2 VP2 gene virus-like particles in mice.

Authors:  Zhong-Hua Deng; Ye-Xia Hao; Li-Hong Yao; Zhi-Ping Xie; Han-Chun Gao; Le-Yun Xie; Li-li Zhong; Bing Zhang; You-De Cao; Zhao-Jun Duan
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

3.  Effects of Serial Skin Testing with Purified Protein Derivative on the Level and Quality of Antibodies to Complex and Defined Antigens in Mycobacterium bovis-Infected Cattle.

Authors:  W Ray Waters; Mitchell V Palmer; Molly R Stafne; Kristin E Bass; Mayara F Maggioli; Tyler C Thacker; Rick Linscott; John C Lawrence; Jeffrey T Nelson; Javan Esfandiari; Rena Greenwald; Konstantin P Lyashchenko
Journal:  Clin Vaccine Immunol       Date:  2015-04-08

4.  Diagnostic relevance of immunoglobulin G avidity for hepatitis A virus.

Authors:  Anne-Marie Roque-Afonso; Liliane Grangeot-Keros; Bénédicte Roquebert; Delphine Desbois; Jean-Dominique Poveda; Vincent Mackiewicz; Elisabeth Dussaix
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

5.  Changes in avidity and level of immunoglobulin G antibodies to Mycobacterium tuberculosis in sera of patients undergoing treatment for pulmonary tuberculosis.

Authors:  Lenka M Pereira Arias-Bouda; Sjoukje Kuijper; Anouk Van der Werf; Lan N Nguyen; Henk M Jansen; Arend H J Kolk
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

Review 6.  Standardization of Assays That Detect Anti-Rubella Virus IgG Antibodies.

Authors:  Wayne Dimech; Liliane Grangeot-Keros; Christelle Vauloup-Fellous
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

7.  Humoral immune response to primary rubella virus infection.

Authors:  Kim M Wilson; Carlie Di Camillo; Larissa Doughty; Elizabeth M Dax
Journal:  Clin Vaccine Immunol       Date:  2006-03

8.  Avidity Studies in Anisakis simplex-Associated Allergic Diseases.

Authors:  Carmen Cuéllar; Ana Valls; Consolación de Frutos; Marta Rodero; Alvaro Daschner
Journal:  J Allergy (Cairo)       Date:  2013-05-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.